SequelSEC

INTEGRA LIFESCIENCES HOLDINGS CORP IART

Surgical & Medical Instruments & Apparatus · CIK 0000917520 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$418.76M
Fiscal year ended 2026-06-30
Operating income
$19.28M
Fiscal year ended 2026-06-30
Free cash flow
$10.50M
Fiscal year ended 2026-06-30

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported revenue of $418.76M and net income of $4.48M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from INTEGRA LIFESCIENCES HOLDINGS CORP’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

INTEGRA LIFESCIENCES HOLDINGS CORP income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$418.76M$391.92M$434.92M$402.06M$415.60M$382.65M$442.65M$380.83M$418.18M$368.87M
Cost of revenue$199.02M$174.94M$214.06M$195.07M$206.27M$188.22M$193.57M$180.60M$192.26M$162.04M
Gross profit$219.74M$216.98M$220.86M$206.99M$209.33M$194.43M$249.07M$200.24M$225.92M$206.83M
Operating income$19.28M$11.47M$23.04M$11.76M-$512.67M-$15.50M$35.63M-$8.15M-$3.03M$3.96M
Net income$4.48M-$4.62M-$1.70M-$5.40M-$484.07M-$25.29M$19.44M-$10.70M-$12.40M-$3.28M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 78.17Mshares 76.95MUnavailableshares 76.75Mshares 76.70Mshares 76.46MUnavailableshares 76.45Mshares 77.41Mshares 77.74M
Pretax income$4.74M-$2.41M$4.31M-$6.82M-$530.95M-$30.04M$22.54M-$20.36M-$15.18M-$5.23M
Income tax expense$262.00K$2.21M$6.01M-$1.42M-$46.88M-$4.74M$3.11M-$9.67M-$2.78M-$1.95M
Diluted EPS$0.06$-0.06Unavailable$-0.07$-6.31$-0.33Unavailable$-0.14$-0.16$-0.04
Selling, general & administrative$172.44M$178.24M$169.27M$169.05M$179.89M$181.50M$178.52M$177.19M$195.47M$165.80M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

INTEGRA LIFESCIENCES HOLDINGS CORP balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$214.42M$236.81M$235.05M$232.19M$217.91M$239.10M$246.38M$215.16M$215.24M$591.91M
Total assets$3.56B$3.58B$3.60B$3.65B$3.67B$4.05B$4.04B$4.07B$4.07B$4.08B
Current assets$1.19B$1.17B$1.16B$1.14B$1.14B$1.11B$1.08B$1.10B$1.11B$1.42B
Total liabilities$2.52B$2.54B$2.56B$2.61B$2.63B$2.53B$2.49B$2.54B$2.54B$2.48B
Current liabilities$330.88M$346.85M$455.98M$364.05M$929.81M$918.45M$922.13M$912.56M$328.32M$302.39M
Total equity incl. NCI$1.04B$1.04B$1.04B$1.04B$1.04B$1.52B$1.55B$1.52B$1.53B$1.60B
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$492.00M$495.04M$492.74M$489.11M$465.13M$445.42M$429.09M$436.93M$421.78M$403.42M
Accounts receivable$267.19M$264.41M$278.85M$262.16M$284.51M$252.45M$272.37M$248.30M$271.16M$241.09M
Goodwill$611.14M$613.25M$615.16M$615.20M$616.43M$1.11B$1.10B$1.12B$1.10B$1.04B
Long-term debt$707.19M$716.88M$726.56M$736.25M$745.94M$755.62M$760.47M$765.31M$770.16M$775.00M
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

INTEGRA LIFESCIENCES HOLDINGS CORP cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow$22.80M$9.80M$11.82M$40.91M$8.92M-$11.26M$50.74M$22.48M$40.40M$15.76M
Capital expenditures$12.31M$14.85M$17.21M$15.16M$20.15M$28.92M$29.60M$29.65M$29.71M$15.46M
Investing cash flow-$43.28M-$14.85M-$34.91M-$15.59M-$21.65M-$35.92M-$4.25M-$10.40M-$322.20M-$53.96M
Financing cash flow-$818.00K$8.30M$24.34M-$10.24M-$21.14M$35.38M-$7.15M-$19.92M-$93.75M$358.68M
Net change in cash-$22.39M$1.76M$2.86M$14.27M-$21.19M-$7.27M$31.22M-$79.00K-$376.67M$315.50M
Stock-based compensation$5.84M$5.16M$5.84M$5.58M$5.30M$1.87M$7.15M$4.38M$7.24M$5.60M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailable$0$0UnavailableUnavailable$2.47M$0$50.00M$0
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

INTEGRA LIFESCIENCES HOLDINGS CORP derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow$10.50M-$5.04M-$5.40M$25.75M-$11.23M-$40.18M$21.14M-$7.16M$10.69M$291.00K
Gross margin52.5%55.4%50.8%51.5%50.4%50.8%56.3%52.6%54.0%56.1%
Operating margin4.6%2.9%5.3%2.9%-123.4%-4.0%8.0%-2.1%-0.7%1.1%
FCF margin2.5%-1.3%-1.2%6.4%-2.7%-10.5%4.8%-1.9%2.6%0.1%
SBC / revenue1.4%1.3%1.3%1.4%1.3%0.5%1.6%1.2%1.7%1.5%
Current ratio3.60x3.38x2.54x3.14x1.23x1.21x1.17x1.20x3.39x4.68x
Revenue YoY growth0.8%2.4%-1.7%5.6%-0.6%3.7%11.5%-0.4%9.7%-3.1%
Net margin1.1%Unavailable-0.4%-1.3%-116.5%Unavailable4.4%-2.8%UnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue2.9%3.8%4.0%3.8%4.8%7.6%6.7%7.8%7.1%4.2%
Long-term debt / equity0.68xUnavailableUnavailable0.71xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate5.5%Unavailable139.5%UnavailableUnavailableUnavailable13.8%UnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IART in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-29View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-05-05View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.